CSPC’s Novel Cancer Drug Enters U.S. Clinical Trials

CSPC Pharmaceutical Group (HK:1093) has released an update.

CSPC Pharmaceutical Group Limited has announced that its antibody-drug conjugate, SYS6023, has received approval from the U.S. FDA for clinical trials targeting advanced solid tumors. This follows earlier clinical trial approval in China and showcases the product’s promising anti-tumor effects across various cancers, with multiple patent applications submitted.

For further insights into HK:1093 stock, check out TipRanks’ Stock Analysis page.